Page 65 - HIVMED_v21_i1.indb

Page 39 of 39 Guideline

69. Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily 85. Hennig S, Svensson EM, Niebecker R, et al. Population pharmacokinetic drug-drug
darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. interaction pooled analysis of existing data for rifabutin and HIV PIs. J Antimicrob
2011;25(7):929–939. Chemother. 2016;71(5):1330–1340. https://doi.org/10.1093/jac/dkv470
70. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir 86. Bartlett JG, Gallant JE, Pham PA (eds). Medical management of HIV infection.
compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir 15th ed. Baltimore, MD: John Hopkins University Press, 2009–2010; 556 pp.
and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients:
96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic 87. Gilbert DN, Moellering RC, Eliopoulos GM, et al. (eds). The Sanford Guide to
Syndr. 2010;53(3):323–332. https://doi.org/10.1097/QAI.0b013e 3181c990bf antimicrobial therapy. 42nd ed. Sperryville, Virginia: Antimicrobial Therapy, Inc.,
2012; 232 pp.
71. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily 88. HIV Medicine Association of the Infectious Diseases Society of America. Clinical
atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple practice guideline for the management of chronic kidney disease in patients
virologic failures. AIDS. 2006;20(5):711–718. infected with HIV: 2014 update. Clin Infect Dis. 2014;59(9):e96–e138.
72. Boyd MA, Moore CL, Molina JM, et al. Baseline HIV-1 resistance, virological
outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory 89. Van Coppenhagen B, Duvenage HS. Prevalence of depression in people living
analysis. Lancet HIV. 2015;2(2):e42–e51. https://doi.org/10.1016/S2352- with HIV and AIDS at the Kalafong Provincial Tertiary Hospital Antiretroviral
3018(14)00061-7 Clinic. S Afr J Psychiatr. 2019;25:1175.
90. Jong E, Conradie F, Berhanu R, et al. Consensus statement: Management of
73. Hill AM, Venter F. The unexpected success of NRTIs in second-line treatment. drug-induced liver injury in HIV-positive patients treated for TB. S Afr J HIV Med.
Lancet Infect Dis. 2018;18(1):3–5. https://doi.org/10.1016/S1473-3099(17)30631-X 2013;14(3):7. https://doi.org/10.4102/sajhivmed.v14i3.63
74. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression 91. SEMDSA Type 2 Diabetes Guidelines Expert Committee. SEMDSA 2017 guidelines
with raltegravir plus etravirine and darunavir/ritonavir among treatment- for the management of type 2 diabetes mellitus2017 [homepage on the
experienced patients infected with multidrug-resistant HIV: Results of the ANRS Internet] [cited 2020 June 1]. Available from: https://www.semdsa.org.za/
139 TRIO trial. Clin Infect Dis. 2009;49(9):1441–1449. images/647-4385-1-PB.pdf
75. Moorhouse M, Maartens G, Venter WDF, et al. Third-line antiretroviral therapy 92. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune
program in the South African public sector: Cohort description and virological reconstitution inflammatory syndrome in HIV-1-infected individuals: Proposed
outcomes. J Acquir Immune Defic Syndr. 2019;80(1):73–78. https://doi. clinical case definitions. Lancet Infect Dis. 2010;10(11):791–802.
org/10.1097/QAI.0000000000001883
76. Grinsztejn B, Hughes MD, Ritz J, et al. Third-line antiretroviral therapy in low- 93. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution
inflammatory syndrome: Case definitions for use in resource-limited settings.
income and middle-income countries (ACTG A5288): A prospective strategy Lancet Infect Dis. 2008;8(8):516–523. https://doi.org/10.1016/S1473-3099(08)
study. Lancet HIV. 2019;6(9):e588–e600. 70184-1
77. Meintjes G, Dunn L, Coetsee M, et al. Third-line antiretroviral therapy in Africa: 94. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial
Effectiveness in a Southern African retrospective cohort study. AIDS Res Ther. of prednisone for paradoxical tuberculosis-associated immune reconstitution
2015;12:39. https://doi.org/10.1186/s12981-015-0081-8 inflammatory syndrome. AIDS. 2010;24(15):2381–2390. https://doi.org/
78. Gandhi RT, Tashima KT, Smeaton LM, et al. Long-term outcomes in a large 10.1097/QAD.0b013e32833dfc68
randomized trial of HIV-1 salvage therapy: 96-week results of AIDS Clinical Trials 95. Meintjes G, Sonderup MW. A practical approach to the diagnosis and
Group A5241 (OPTIONS). J Infect Dis. 2019;221:1407–1415. https://doi.org/ management of paradoxical tuberculosis immune reconstitution inflammatory
10.1093/infdis/jiz281 syndrome. Contin Med Educ. 2011;29(10):410–417.
79. Stevens WS, Wallis CL, Sanne I, Venter F. Will etravirine work in patients failing 96. Meintjes G, Stek C, Blumenthal L, et al. Prednisone for the prevention
nonnucleoside reverse transcriptase inhibitor-based treatment in southern of paradoxical tuberculosis-associated IRIS. N Engl J Med. 2018;379(20):
Africa? J Acquir Immune Defic Syndr. 2009;52(5):655–656. 1915–1925. https://doi.org/10.1056/NEJMoa1800762
80. Meintjes G, Brust JCM, Nuttall J, Maartens G. Management of active tuberculosis 97. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy
in adults with HIV. Lancet HIV. 2019;6(7):e463–e474. https://doi.org/10.1016/ to prevent tuberculosis: A randomised double-blind, placebo-controlled trial.
S2352-3018(19)30154-7 Lancet. 2014;384(9944):682–690. https://doi.org/10.1016/S0140-6736(14)
81. Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for 60162-8
patients co-infected with tuberculosis and HIV: A multicenter, noncomparative, 98. Group TAS, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid
open-label, randomized trial. Clin Infect Dis. 2019;70:549–556. https://doi.org/ preventive therapy in Africa. N Engl J Med. 2015;373(9):808–822. https://doi.
10.2139/ssrn.3244943 org/10.1056/NEJMoa1507198
82. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose 99. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized
lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob screening rule for tuberculosis in people living with HIV in resource-constrained
Agents Chemother. 2004;48(5):1553–1560. settings: Individual participant data meta-analysis of observational studies. PLoS
83. Decloedt EH, Maartens G, Smith P, Merry C, Bango F, McIlleron H. The safety, Med. 2011;8(1):e1000391. https://doi.org/10.1371/journal.pmed.1000391
effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV- 100. Gupta A, Montepiedra G, Aaron L, et al. Isoniazid preventive therapy in
infected adults on rifampicin-based antitubercular therapy. PLoS One. HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):
2012;7(3):e32173. 1333–1346. https://doi.org/10.1056/NEJMoa1813060
84. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. 101. Kalk E, Heekes A, Mehta U, et al. Safety and effectiveness of isoniazid preventive
Cochrane Database Syst Rev. 2007(4):CD005159. https://doi.org/10.1002/ therapy in HIV-positive pregnant women on art: An observational study using
14651858.CD005159.pub2 linked population data. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciz1224

http://www.sajhivmed.org.za 57 Open Access